文章：

放疗后使用免疫检查点抑制剂可提高IV期肺癌患者的总生存率

Immune Checkpoint Inhibitors after Radiation Therapy Improve Overall Survival Rates in Patients with Stage IV Lung Cancer

原文发布日期：25 August 2023

DOI: 10.3390/cancers15174260

类型: Article

开放获取: 是

英文摘要：

This exploratory and retrospective study aimed to evaluate whether there is a difference in the overall survival (OS) rates of patients with stage IV lung cancer who underwent radiation therapy (RT) depending on the presence or absence of immune checkpoint inhibitors (ICIs) and the timing of their use. Eighty patients with histologically confirmed stage IV lung cancer were enrolled, and ICIs were administered to thirty (37.5%). ICIs were administered before RT and after RT in 11 and 20 patients, respectively. The median follow-up period was 6 (range: 1–37) months. Patients treated with ICIs had significantly better OS rates than those not treated with ICIs (p< 0.001). The 6-month OS rates in patients treated with and without ICIs were 76.3% and 34.5%, respectively. The group that received ICI therapy after RT had a significantly better OS rate than the group that received ICI therapy prior to RT (6-month OS: 94.7% vs. 40.0%,p< 0.001). In the multivariate analysis, performance status (0–1 vs. 2–4) and ICI use after RT were significant factors for OS (p= 0.032 andp< 0.001, respectively). Our results suggest that ICI administration after RT may prolong the OS of patients with stage IV lung cancer.

摘要翻译： 

本探索性回顾研究旨在评估接受放射治疗（RT）的IV期肺癌患者，其总生存率（OS）是否因免疫检查点抑制剂（ICI）的使用与否及其使用时机而存在差异。研究共纳入80例经组织学确诊的IV期肺癌患者，其中30例（37.5%）接受了ICI治疗。在ICI治疗组中，11例患者于RT前接受ICI治疗，20例于RT后接受。中位随访时间为6个月（范围：1-37个月）。接受ICI治疗的患者OS率显著优于未接受者（p<0.001）。接受与未接受ICI治疗患者的6个月OS率分别为76.3%和34.5%。RT后接受ICI治疗组的OS率显著优于RT前接受治疗组（6个月OS率：94.7% vs. 40.0%，p<0.001）。多变量分析显示，体能状态（0-1分 vs. 2-4分）与RT后使用ICI是影响OS的显著因素（p值分别为0.032和<0.001）。本研究结果表明，RT后给予ICI治疗可能延长IV期肺癌患者的总生存期。

原文链接：

Immune Checkpoint Inhibitors after Radiation Therapy Improve Overall Survival Rates in Patients with Stage IV Lung Cancer